Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
High serum concentrations of insulin-like growth factor-1 (IGF-1) are associated with an increased risk of breast, prostate, colorectal, and lung cancer whereas IGF binding protein-3 (IGFBP-3) seems to exert a protective effect. Therefore, patients may benefit from low IGF-1 levels and high IGFBP-3 levels. This study evaluated whether adjuvant anthracycline-containing chemotherapy modulates IGF-1 and/or IGFBP-3 serum levels in breast cancer patients. In 18 patients undergoing adjuvant treatment for primary breast cancer, IGF-1 and IGFBP-3 serum levels were measured with immunoassays during chemotherapy regimens of either 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC). Mean pre-treatment values of IGF-1 and IGFBP-3 were 124+/-13 and 3698+/-186 ng/ml, respectively. No significant changes in IGF-1 and IGFBP-3 serum concentrations were observed during adjuvant anthracycline-containing chemotherapy. IGF-1 levels significantly correlated with IGFBP-3 levels before and during chemotherapy. In conclusion, these chemotherapy regimens do not seem to modulate IGF-1 or IGFBP-3 levels in a favourable or unfavourable way.
Center for Tumor Detection and Prevention, Rorschacherstrasse 150, CH-9006 St. Gallen, Switzerland. gfuerstenberger@sg.zetup.ch
Gregor
G
Fürstenberger
Eva
E
Senn
Rudolf
R
Morant
Barbara
B
Bolliger
Hans-Jörg
HJ
Senn
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood* / Q000187:drug effects; D007334:Insulin-Like Growth Factor I / Q000032:analysis* / Q000187:drug effects; D008875:Middle Aged
D018972:Insulin-Like Growth Factor Binding Protein 3; D015251:Epirubicin; D007334:Insulin-Like Growth Factor I; D003520:Cyclophosphamide; D005472:Fluorouracil